ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: A specially modified virus called ONYX-015 may be able to kill tumor cells while
leaving normal cells undamaged. Drugs used in chemotherapy use different ways to stop tumor
cells from dividing so they stop growing or die. Combining ONYX-015 with chemotherapy may
kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of ONYX-015 combined with cisplatin and
fluorouracil in treating patients who have advanced head and neck cancer.